tiprankstipranks
Trending News
More News >
Nanobiotix SA (FR:NANO)
:NANO
France Market

Nanobiotix (NANO) Stock Forecast & Price Target

Compare
12 Followers
See the Price Targets and Ratings of:

NANO Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Nanobiotix
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NANO Stock 12 Month Forecast

Average Price Target

€13.50
▲(224.52%Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Nanobiotix in the last 3 months. The average price target is €13.50 with a high forecast of €17.00 and a low forecast of €10.00. The average price target represents a 224.52% change from the last price of €4.16.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","18":"€18","5.25":"€5.25","9.5":"€9.5","13.75":"€13.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.25,9.5,13.75,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"Jun<br/>2024","9":"Dec<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.975,4.053846153846154,5.132692307692308,6.211538461538462,7.290384615384616,8.36923076923077,9.448076923076922,10.526923076923076,11.60576923076923,12.684615384615384,13.763461538461538,14.842307692307692,15.921153846153844,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.975,3.7846153846153845,4.594230769230769,5.403846153846153,6.213461538461539,7.023076923076923,7.832692307692307,8.642307692307693,9.451923076923077,10.261538461538462,11.071153846153846,11.88076923076923,12.690384615384614,{"y":13.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.975,3.5153846153846153,4.055769230769231,4.596153846153847,5.136538461538462,5.676923076923078,6.217307692307693,6.757692307692308,7.298076923076923,7.838461538461539,8.378846153846155,8.91923076923077,9.459615384615386,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.61,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.445,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.968,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.812,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.464,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.244,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.975,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€17.00Average Price Target€13.50Lowest Price Target€10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on FR:NANO
TipRanks AITipRanks
Not Ranked
TipRanks
€4
Hold
-3.85%
Downside
Reiterated
06/05/25
The overall score of 57 reflects a mixed outlook. The company's strategic partnerships and clinical advancements are significant positives, but these are overshadowed by poor financial performance, characterized by declining revenues and negative profitability. Technical indicators are favorable, but the overbought condition warrants caution.
H.C. Wainwright Analyst forecast on FR:NANO
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
€10
Buy
140.38%
Upside
Reiterated
05/28/25
Promising Clinical Developments and Strategic Partnerships Propel Nanobiotix to a Buy Rating
Stifel Nicolaus Analyst forecast on FR:NANO
Clémence ThiersStifel Nicolaus
Stifel Nicolaus
€16€17
Buy
308.65%
Upside
Reiterated
05/06/25
Nanobiotix SA (NANO:FP) PT Raised to EUR17 at StifelStifel analyst Clemence Thiers raised the price target on Nanobiotix SA (NANO:FP) to EUR17.00 (from EUR16.00) while maintaining a Buy rating.
Jefferies
€10.5€9.5
Buy
128.37%
Upside
Reiterated
09/23/24
Nanobiotix SA (NANO:FP) PT Lowered to EUR9.50 at JefferiesJefferies analyst Lucy Codrington lowered the price target on Nanobiotix SA (NANO:FP) to EUR9.50 (from EUR10.50) while maintaining a Buy rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on FR:NANO
TipRanks AITipRanks
Not Ranked
TipRanks
€4
Hold
-3.85%
Downside
Reiterated
06/05/25
The overall score of 57 reflects a mixed outlook. The company's strategic partnerships and clinical advancements are significant positives, but these are overshadowed by poor financial performance, characterized by declining revenues and negative profitability. Technical indicators are favorable, but the overbought condition warrants caution.
H.C. Wainwright Analyst forecast on FR:NANO
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
€10
Buy
140.38%
Upside
Reiterated
05/28/25
Promising Clinical Developments and Strategic Partnerships Propel Nanobiotix to a Buy Rating
Stifel Nicolaus Analyst forecast on FR:NANO
Clémence ThiersStifel Nicolaus
Stifel Nicolaus
€16€17
Buy
308.65%
Upside
Reiterated
05/06/25
Nanobiotix SA (NANO:FP) PT Raised to EUR17 at StifelStifel analyst Clemence Thiers raised the price target on Nanobiotix SA (NANO:FP) to EUR17.00 (from EUR16.00) while maintaining a Buy rating.
Jefferies
€10.5€9.5
Buy
128.37%
Upside
Reiterated
09/23/24
Nanobiotix SA (NANO:FP) PT Lowered to EUR9.50 at JefferiesJefferies analyst Lucy Codrington lowered the price target on Nanobiotix SA (NANO:FP) to EUR9.50 (from EUR10.50) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nanobiotix

1 Month
xxx
Success Rate
4/11 ratings generated profit
36%
Average Return
+10.56%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 36.36% of your transactions generating a profit, with an average return of +10.56% per trade.
3 Months
xxx
Success Rate
5/11 ratings generated profit
45%
Average Return
+30.59%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +30.59% per trade.
1 Year
Swayampakula RamakanthH.C. Wainwright
Success Rate
7/11 ratings generated profit
64%
Average Return
+28.46%
reiterated a buy rating 12 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +28.46% per trade.
2 Years
xxx
Success Rate
6/11 ratings generated profit
55%
Average Return
+6.40%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +6.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NANO Analyst Recommendation Trends

Rating
Nov 24
Dec 24
Mar 25
Apr 25
May 25
Strong Buy
7
7
8
8
9
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
7
8
8
9
In the current month, NANO has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NANO average Analyst price target in the past 3 months is 13.50.
Each month's total comprises the sum of three months' worth of ratings.

NANO Financial Forecast

NANO Earnings Forecast

Next quarter’s earnings estimate for NANO is -€0.31 with a range of -€0.31 to -€0.31. The previous quarter’s EPS was ―. NANO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year NANO has Preformed in-line its overall industry.
Next quarter’s earnings estimate for NANO is -€0.31 with a range of -€0.31 to -€0.31. The previous quarter’s EPS was ―. NANO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year NANO has Preformed in-line its overall industry.

NANO Sales Forecast

Next quarter’s sales forecast for NANO is €14.10M with a range of €14.10M to €14.10M. The previous quarter’s sales results were ―. NANO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year NANO has Preformed in-line its overall industry.
Next quarter’s sales forecast for NANO is €14.10M with a range of €14.10M to €14.10M. The previous quarter’s sales results were ―. NANO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year NANO has Preformed in-line its overall industry.

NANO Stock Forecast FAQ

What is FR:NANO’s average 12-month price target, according to analysts?
Based on analyst ratings, Nanobiotix SA’s 12-month average price target is 13.50.
    What is FR:NANO’s upside potential, based on the analysts’ average price target?
    Nanobiotix SA has 224.52% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Nanobiotix SA a Buy, Sell or Hold?
          Nanobiotix SA has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Nanobiotix SA’s share price target?
            The average share price target for Nanobiotix SA is 13.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €17.00 ,and the lowest forecast is €10.00. The average share price target represents 224.52% Increase from the current price of €4.16.
              What do analysts say about Nanobiotix SA?
              Nanobiotix SA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Nanobiotix SA?
                To buy shares of FR:NANO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis